Impact of Age, Comorbidity, and FIGO Stage on Treatment Choice and Mortality in Older Danish Patients with Gynecological Cancer: A Retrospective Register-Based Cohort Study

Overview

Journal Drugs Real World Outcomes

Date 2018 Nov 22

PMID 30460662

Citations 6

Authors

Sambavy Nadaraja

Trine Lembrecht Jorgensen

Lars-Erik Matzen

Jorn Herrstedt

Affiliations

Soon will be listed here.

Abstract

Background: The number of older patients with cancer is increasing in general, and ovarian and endometrial cancer are to a large extent cancers of the elderly. Older patients with cancer have a high prevalence of comorbidity. Comorbidity and age may be predictive of treatment choice and mortality in older patients with cancer along with stage and performance status.

Objectives: The aim of this study was to describe comorbidity in a population of older Danish patients with gynecological cancer, and to evaluate the predictive value of comorbidity and age on treatment choice and cancer-specific and all-cause mortality.

Materials And Methods: In this retrospective study, we included 459 patients aged ≥ 70 years. Patients were diagnosed with cervical, endometrial, or ovarian cancer from 1 January, 2007 to 31 December, 2011 and were evaluated and/or treated at Odense University Hospital. Comorbidity was assessed using the Charlson Comorbidity Index. Treatment was classified as curative intended, palliative intended, or no treatment.

Results: Age, International Federation of Gynecology and Obstetrics (FIGO) stage, and performance status were found to be significant predictors of treatment choice, while comorbidity was not. Multivariate analyses showed that both cancer-specific and all-cause mortality were significantly associated with treatment choice, FIGO stage, and performance status. Age was not associated with mortality, with the exception of ovarian cancer, where age was associated with all-cause mortality. Comorbidity was not an independent predictor of treatment choice or mortality.

Conclusions: In our population of older Danish patients with gynecological cancer, age, FIGO stage, and performance status were predictors of treatment choice, while comorbidity was not. Treatment choice, FIGO stage, and performance status were significantly associated with both cancer-specific and all-cause mortality. Age was only associated with mortality in ovarian cancer, while comorbidity was not associated with mortality.

Citing Articles

Endometrial Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry Number 032/034-OL, September 2022). Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer, Geriatric....

Emons G, Steiner E, Vordermark D, Uleer C, Paradies K, Tempfer C Geburtshilfe Frauenheilkd. 2023; 83(8):919-962.

PMID: 37588260 PMC: 10427205. DOI: 10.1055/a-2066-2051.

The preoperative G8 geriatric screening tool independently predicts survival in older patients with endometrial cancer: results of a retrospective single-institution cohort study.

Anic K, Altehoefer C, Krajnak S, Schmidt M, Schwab R, Linz V J Cancer Res Clin Oncol. 2022; 149(2):851-863.

PMID: 35212815 PMC: 9931812. DOI: 10.1007/s00432-022-03934-1.

Construction and comprehensive analysis of the competing endogenous RNA network in endometrial adenocarcinoma.

Feng C, Cui L, Jin Z, Sun L, Wang X, Chi X BMC Genom Data. 2022; 23(1):10.

PMID: 35123404 PMC: 8818217. DOI: 10.1186/s12863-022-01028-y.

Practical brachytherapy solutions to an age-old quandary.

Thiruthaneeswaran N, Tharmalingam H, Hoskin P Tech Innov Patient Support Radiat Oncol. 2021; 16:39-47.

PMID: 33385072 PMC: 7769855. DOI: 10.1016/j.tipsro.2020.09.004.

Ten years of experience with endometrial cancer treatment in a single Brazilian institution: Patient characteristics and outcomes.

Anton C, Kleine R, Mayerhoff E, Diz M, de Freitas D, Carvalho H PLoS One. 2020; 15(3):e0229543.

PMID: 32134921 PMC: 7058346. DOI: 10.1371/journal.pone.0229543.

References

Extermann M . Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol. 2000; 35(3):181-200. DOI: 10.1016/s1040-8428(00)00090-1. View

Tingulstad S, Skjeldestad F, Halvorsen T, Hagen B . Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol. 2003; 101(5 Pt 1):885-91. DOI: 10.1016/s0029-7844(03)00123-6. View

OMalley C, Cress R, Campleman S, Leiserowitz G . Survival of Californian women with epithelial ovarian cancer, 1994-1996: a population-based study. Gynecol Oncol. 2003; 91(3):608-15. DOI: 10.1016/j.ygyno.2003.08.010. View

Read W, Tierney R, Page N, Costas I, Govindan R, Spitznagel E . Differential prognostic impact of comorbidity. J Clin Oncol. 2004; 22(15):3099-103. DOI: 10.1200/JCO.2004.08.040. View

Maas H, Kruitwagen R, Lemmens V, Goey S, Janssen-Heijnen M . The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. Gynecol Oncol. 2005; 97(1):104-9. DOI: 10.1016/j.ygyno.2004.12.026. View

Bois A, Rochon J, Lamparter C, Pfisterer J . Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Int J Gynecol Cancer. 2005; 15(2):183-91. DOI: 10.1111/j.1525-1438.2005.15202.x. View

Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J . Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005; 43(11):1130-9. DOI: 10.1097/01.mlr.0000182534.19832.83. View

Hilpert F, Bois A, Greimel E, Hedderich J, Krause G, Venhoff L . Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >or=70 years with advanced ovarian cancer--a study by the AGO OVAR Germany. Ann Oncol. 2006; 18(2):282-7. DOI: 10.1093/annonc/mdl401. View

Wedding U, Honecker F, Bokemeyer C, Pientka L, Hoffken K . Tolerance to chemotherapy in elderly patients with cancer. Cancer Control. 2007; 14(1):44-56. DOI: 10.1177/107327480701400106. View

10.

Susini T, Amunni G, Busi E, Villanucci A, Carriero C, Taddei G . Ovarian cancer in the elderly: feasibility of surgery and chemotherapy in 89 geriatric patients. Int J Gynecol Cancer. 2007; 17(3):581-8. DOI: 10.1111/j.1525-1438.2007.00836.x. View

11.

Elit L, Bondy S, Chen Z, Paszat L . A tale of two time periods: ovarian cancer trends in Ontario. Curr Oncol. 2007; 14(2):57-60. PMC: 1891199. DOI: 10.3747/co.2007.106. View

12.

Janssen-Heijnen M, Maas H, Houterman S, Lemmens V, Rutten H, Coebergh J . Comorbidity in older surgical cancer patients: influence on patient care and outcome. Eur J Cancer. 2007; 43(15):2179-93. DOI: 10.1016/j.ejca.2007.06.008. View

13.

Tetsche M, Norgaard M, Jacobsen J, Wogelius P, Sorensen H . Comorbidity and ovarian cancer survival in Denmark, 1995-2005: a population-based cohort study. Int J Gynecol Cancer. 2007; 18(3):421-7. DOI: 10.1111/j.1525-1438.2007.01036.x. View

14.

Tetsche M, Dethlefsen C, Pedersen L, Sorensen H, Norgaard M . The impact of comorbidity and stage on ovarian cancer mortality: a nationwide Danish cohort study. BMC Cancer. 2008; 8:31. PMC: 2266760. DOI: 10.1186/1471-2407-8-31. View

15.

Moore K, Reid M, Fong D, Myers T, Landrum L, Moxley K . Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply?. Gynecol Oncol. 2008; 110(2):133-9. DOI: 10.1016/j.ygyno.2008.03.008. View

16.

Elit L, Bondy S, Paszat L, Holowaty E, Thomas G, Stukel T . Surgical outcomes in women with ovarian cancer. Can J Surg. 2008; 51(5):346-54. PMC: 2556534. View

17.

Petri A, Kjaer S, Christensen I, Blaakaer J, Hogdall E, Jeppesen U . Validation of epithelial ovarian cancer and fallopian tube cancer and ovarian borderline tumor data in the Danish Gynecological Cancer Database. Acta Obstet Gynecol Scand. 2009; 88(5):536-42. DOI: 10.1080/00016340902846064. View

18.

Smith B, Smith G, Hurria A, Hortobagyi G, Buchholz T . Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009; 27(17):2758-65. DOI: 10.1200/JCO.2008.20.8983. View

19.

Valderas J, Starfield B, Sibbald B, Salisbury C, Roland M . Defining comorbidity: implications for understanding health and health services. Ann Fam Med. 2009; 7(4):357-63. PMC: 2713155. DOI: 10.1370/afm.983. View

20.

Yasmeen S, Xing G, Morris C, Chlebowski R, Romano P . Comorbidities and mammography use interact to explain racial/ethnic disparities in breast cancer stage at diagnosis. Cancer. 2011; 117(14):3252-61. DOI: 10.1002/cncr.25857. View